title: Targeted therapy in sarcomas other than GIST tumors.
abstract: Non-GIST soft tissue sarcomas are a heterogeneous grouping of mesenchymal tumors that comprise less than 1% of adult malignancies. Treatment continues to be based on cytotoxic chemotherapy regimens. However, characterization of the molecular pathway deregulations that drive these tumors has led to the emergence of more customized treatment options. In this review, we focus on the multitude of molecular inhibitors targeting angiogenesis and cell cycle pathways being tested in clinical trials.
authors.affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
authors.forename: Douglas
authors.initials: D
authors.lastname: Sborov
authors.forename: James L
authors.initials: JL
authors.lastname: Chen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects; D005770:Gastrointestinal Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D046152:Gastrointestinal Stromal Tumors / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy; D012509:Sarcoma / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents
keywords: angiogenesis inhibitors; cell cycle inhibitors; non-GIST soft tissue sarcoma; targeted therapy